Bcal Diagnostics Share Price and Company Fundamentals
Last traded: Yesterday at 12:46 AM
BCAL Diagnostics Limited, a biotechnology company, engages in developing a novel blood screening test to support the early diagnosis and monitoring of breast cancer in Australia. It is involved in the development and commercialization of BREASTESTplus; Avantect Pancreatic; Avantect Ovarian; BREASTESTplus 2; BREASTEST Monitor; and Avantect multi-cancer test. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Key Metrics
PE ratio
-
PB ratio
-
Dividend yield
0.00%
Beta
0.72
Market cap
$23.60M
Enterprise value
$28.92M
Company profile
| Industry / Sector | Diagnostics & Research / Healthcare |
|---|---|
| Website | https://www.bcaldiagnostics.com |
| Mailing address | 50 Clarence Street Suite 506, Level 5 Sydney NSW 2000 Australia |
| Phone / Fax | 61 2 9078 7671 / |
Dividends
More: Bcal Diagnostics Dividend history, yield and payout ratio
Dividend yield
0.00%
Dividend amount
$-
Payout ratio
-
5Y Avg. yield
-%
Bcal Diagnostics paid $- dividend and the ex-dividend date was -.The dividend payout ratio is -. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.
Company Executives
As of Nov 2026, following are the company executives and directors listed on Bcal Diagnostics.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Ms. Jayne Andrea Shaw | Co-Founder & Executive Chairman | ||
| Ms. Anne-Louise Arnett | Chief Executive Officer | ||
| Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), CA, MAICD | CFO & Company Secretary | 72 | |
| Mr. Sean Alexander Kennedy | Director of Corporate Finance |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-300.54%
Return on assets
-50.29%
Return on equity
-273.29%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Bcal Diagnostics is 23.60M and its enterprise value is 28.92M. The enterprise value to revenue ratio of BDX is 12.30. The enterprise value to EBITDA ratio of BDX is -4.39.
The BDX's stocks Beta value is 0.72 making it 28% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Bcal Diagnostics (BDX)
Bcal Diagnostics (ASX:BDX) Frequently Asked Questions
1. What is Bcal Diagnostics's Stock Symbol?
Bcal Diagnostics trades on ASX under the ticker symbol "BDX".
2. What is Bcal Diagnostics's stock price today?
One share of BDX stock can currently be purchased for approximately $0.064.
3. How can I contact Bcal Diagnostics?
Bcal Diagnostics's mailing address is 50 Clarence Street Suite 506, Level 5 Sydney NSW 2000 Australia. The company can be reached via phone at 61 2 9078 7671.
4. What is Bcal Diagnostics's official website?
The official website of Bcal Diagnostics is https://www.bcaldiagnostics.com.